Infliximab (Remicade) as an adjunct to pegylated-interferon alpha-2b and ribavirin in the treatment of hepatitis C virus infection.
Phase of Trial: Phase II
Latest Information Update: 15 Sep 2017
At a glance
- Drugs Infliximab (Primary) ; Peginterferon alfa-2b; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms PARTNER
- 01 May 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 28 Mar 2011 Planned End Date changed from 1 Sep 2011 to 1 May 2012 as reported by ClinicalTrials.gov.
- 28 Mar 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.